Last reviewed · How we verify
ropivacaine and ketorolac
This combination drug blocks pain signals through local anesthesia (ropivacaine) while simultaneously reducing inflammation and pain via COX inhibition (ketorolac).
This combination drug blocks pain signals through local anesthesia (ropivacaine) while simultaneously reducing inflammation and pain via COX inhibition (ketorolac). Used for Postoperative pain management, Local/regional anesthesia with anti-inflammatory analgesia.
At a glance
| Generic name | ropivacaine and ketorolac |
|---|---|
| Sponsor | University of Aarhus |
| Drug class | Local anesthetic + NSAID combination |
| Target | Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing pain signal transmission in a specific anatomical region. Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation and pain systemically. Together, they provide multimodal analgesia through complementary mechanisms.
Approved indications
- Postoperative pain management
- Local/regional anesthesia with anti-inflammatory analgesia
Common side effects
- Local site reactions (erythema, edema)
- Gastrointestinal effects (ketorolac-related)
- Systemic toxicity from local anesthetic (rare)
Key clinical trials
- Opioid-Free Pain Protocol After Shoulder Arthroplasty (PHASE4)
- Postoperative Pain Management Following Robotic Assisted Sacrocolpopexy (NA)
- Single Shot Exparel vs Catheters in Lower Extremity Trauma (PHASE4)
- Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. (PHASE2, PHASE3)
- Pain Management Study (PHASE4)
- Prospective Opioid-Free AIS Fusion (PHASE4)
- Effect of RECK in Posterior Spinal Fusion (PHASE1, PHASE2)
- LIA vs. LIA + ACB-iPACK Block for Total Knee Arthroplasty (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ropivacaine and ketorolac CI brief — competitive landscape report
- ropivacaine and ketorolac updates RSS · CI watch RSS
- University of Aarhus portfolio CI